Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Postural control the best predictor of stroke rehabilitation outcome

Having good postural control at admission to a skilled nursing facility after a stroke significantly increases elderly patients' chances of achieving a successful discharge to independent living and having good functional status at discharge, study results show.

12 Nov 2012

Radiotherapy protocol deviations: an interview with Dr Nitin Ohri

Radiotherapy is a key component of cancer therapy. A majority of cancer patients get radiotherapy in some form at some point in their disease course. It can be used in a curative setting or in a palliative setting.

12 Nov 2012

Women with ovarian cancer have superior outcomes after surgery at high-volume hospitals

A study by researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) at NewYork-Presbyterian/Columbia University Medical Center, recently e-published ahead of print by the Journal of Clinical Oncology, suggests that women who have surgery for ovarian cancer at high-volume hospitals have superior outcomes than similar patients at low-volume hospitals.

9 Nov 2012

New communication training could help nephrology fellows to discuss serious news with patients

Kidney specialists, or nephrologists, care for a medically complex population and frequently must discuss serious news with patients: giving a diagnosis of kidney disease, explaining the risks and benefits of treatments, and defining care goals at the end of life. Yet nephrologists do not routinely receive formal education on how to engage in these types of conversations.

9 Nov 2012

Plexxikon updates Zelboraf Phase 1 data on BRAF V600E mutation-positive melanoma

Plexxikon today announced that updated Phase 1 clinical data of Zelboraf (vemurafenib) were presented at the Society for Melanoma Research (SMR) 2012 Congress, held November 8-11 in Los Angeles, CA.

8 Nov 2012

Canine lymphoma treatment adds up to cystitis

High cumulative doses of the alkylator cyclophosphamide could be to blame for the development of sterile hemorrhagic cystitis in dogs being treated for lymphoma, indicate the results of a US study.

8 Nov 2012

Surgery-free ileostomy removal shows promise

Temporary percutaneous ileostomy following rectal resection is as effective at preventing anastomotic leakage as conventional loop ileostomy, show the results of an Italian study.

8 Nov 2012

Two-drug combo relieves agitation first time

The majority of advanced cancer patients who experience agitation achieve control after the first dose of an antipsychotic–antiseizure combination is administered, show study results.

8 Nov 2012

Patient recruitment complete for immatics IMA901 Phase 3 trial for renal cell carcinoma

immatics biotechnologies GmbH, a biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer, announced today that it has completed patient recruitment into the pivotal phase 3 trial evaluating its lead cancer vaccine IMA901 for renal cell carcinoma (RCC). The trial has completed patient inclusion and it is expected that around 345 patients will be randomized across 10 countries in the US and Europe.

8 Nov 2012

Stapled Peptide oncology drug candidate exhibits robust efficacy in xenograft cancer models

Aileron Therapeutics, Inc. and its collaborator Roche today announced new results of a preclinical study of its Stapled Peptide oncology drug candidate ATSP-7041, which exhibited robust efficacy in MDM2 and MDMX xenograft cancer models.

8 Nov 2012

Carbohydrate-rich food intake may cause recurrence of colon cancer

Colon cancer survivors whose diet is heavy in complex sugars and carbohydrate-rich foods are far more likely to have a recurrence of the disease than are patients who eat a better balance of foods, a new study by Dana-Farber Cancer Institute researchers indicates.

8 Nov 2012

EpiCept, Immune Pharmaceuticals enter definitive merger agreement

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation today announced that they have entered into a definitive merger agreement. The transaction is anticipated to close during the first quarter of 2013 and is subject to satisfaction of certain customary closing conditions, including the approval of a majority of EpiCept shareholders.

8 Nov 2012

Teva announces additional data from QNASL Phase III program on seasonal allergic rhinitis

Teva Pharmaceutical Industries Ltd. announced today that additional data from the Phase III clinical program for QNASL- (beclomethasone dipropionate) Nasal Aerosol will be presented at the 2012 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Anaheim, CA on November 8-13, 2012.

7 Nov 2012

Synta announces interim results from docetaxel Phase 2b/3 trial on NSCLC

Synta Pharmaceuticals Corp. announced today that interim results from the Phase 2b/3 GALAXY trial will be presented at the Chemotherapy Foundation Symposium in New York City on Friday, November 9 during the 11:45 a.m. session on new agents for lung cancer. Presenting this data at the conference will be Dr. Suresh Ramalingham, Professor, Hematology & Medical Oncology, and Director, Translational Thoracic Malignancies Program, of the Winship Cancer Institute of Emory University.

7 Nov 2012

FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

The US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted unanimously in support of the use of Signifor (pasireotide) for the treatment of patients with Cushing's disease who require medical therapeutic intervention.

7 Nov 2012

Ion AmpliSeq Community Panels from Life Technologies

Life Technologies Corporation today announced Ion AmpliSeq Community Panels, a community-driven solution to gene panel sequencing that leverages the expertise of scientific thought leaders and the Ion Community to create gene panels for conditions ranging from cancer to inherited diseases.

7 Nov 2012

Cloud technology helps researchers collect detailed information from cancer cell samples

Storing music and photos on distant computers via "cloud" technology is nothing new. But Johns Hopkins researchers are now using this tactic to collect detailed information from thousands of cancer cell samples. The goal is to help doctors make better predictions about how a patient's illness will progress and what type of treatment will be most effective.

7 Nov 2012

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

FDA approves Pfizer’s XELJANZ to treat rheumatoid arthritis

Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.

6 Nov 2012

Any hospice better than none at end of life

Nursing home residents with advanced dementia who receive any hospice care during the last 90 days of life receive fewer aggressive treatments and are less likely to die in hospital than their counterparts who do not receive such care, show US study results.

6 Nov 2012

Oncology News and Research

Further Reading

Postural control the best predictor of stroke rehabilitation outcome

Radiotherapy protocol deviations: an interview with Dr Nitin Ohri

Women with ovarian cancer have superior outcomes after surgery at high-volume hospitals

New communication training could help nephrology fellows to discuss serious news with patients

Plexxikon updates Zelboraf Phase 1 data on BRAF V600E mutation-positive melanoma

Canine lymphoma treatment adds up to cystitis

Surgery-free ileostomy removal shows promise

Two-drug combo relieves agitation first time

Patient recruitment complete for immatics IMA901 Phase 3 trial for renal cell carcinoma

Stapled Peptide oncology drug candidate exhibits robust efficacy in xenograft cancer models

Carbohydrate-rich food intake may cause recurrence of colon cancer

EpiCept, Immune Pharmaceuticals enter definitive merger agreement

Teva announces additional data from QNASL Phase III program on seasonal allergic rhinitis

Synta announces interim results from docetaxel Phase 2b/3 trial on NSCLC

FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

Ion AmpliSeq Community Panels from Life Technologies

Cloud technology helps researchers collect detailed information from cancer cell samples

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

FDA approves Pfizer’s XELJANZ to treat rheumatoid arthritis

Any hospice better than none at end of life

Industry Focus eBook - Oncology (3rd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News